First human test of targeted 'Tumor Glow' therapy for tough cancers
NCT ID NCT06640413
Summary
This early-stage study is testing a new radioactive drug, given alone or with an immune-boosting drug, for people with advanced cancers that have a specific marker called FAP. The main goal is to find a safe dose and see how well the body handles the treatment. It is for patients who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAP are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASST Papa Giovanni XXIII Piazza OMS
RECRUITINGBergamo, Bergamo, 24127, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITINGMilan, Milano, 20133, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Istituto Europeo di Oncologia
NOT_YET_RECRUITINGMilan, Milano, 20141, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Via Mariano Semmola
NOT_YET_RECRUITINGNaples, Napoli, 80131, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.